Importantly, although the ITGB4 gene mutation rate was only 2.5% in PAAD, CNV and DNA methylation of the ITGB4 gene were positively and negatively correlated with ITGB4 gene expression, respectively, and both were significantly associated with the survival of patients with PAAD, suggesting that both genetic and epigenetic mechanisms determine ITGB4 levels and significantly impact disease outcome. This evidence concerns the gene ITGB4 and pancreatic adenocarcinoma.